Both treatments use antibodies to combat Ebola. Trials show they can boost survival rates to about 90%
NEWS ABOUT Ebola, a viral disease that kills up to 90% of those it infects, is usually grim. The latest outbreak, in the Democratic Republic of Congo , has thus far killed nearly 1,900 people and rages on. But on August 12th the grimness lifted somewhat with the announcement that two anti-Ebola treatments being tested in the country have proved effective. If administered when the first signs of infection appear, they boost survival rates to about 90%.
The treatments in question employ antibodies. These are special protein molecules made by the immune system in response to infection. They work by locking onto specific parts of invading pathogens, or of body cells infected by those pathogens—either gumming the target up and disabling it or marking it for destruction by other parts of the immune-system.
Prompt use after infection is vital. Overall, 29% of those receiving REGN-EB3 died. But of people treated when their viral loads were still low only 6% succumbed. For mAb114 the numbers were 34% and 11% respectively—superficially worse, but actually indistinguishable, statistically speaking, from the results for REGN-EB3. Two other candidates had significantly worse figures than these, and were therefore rejected by the overseers.
Both REGN-EB3 and mAb114 have histories. Regeneron developed the former in 2016, in response to an Ebola epidemic in West Africa in which 11,000 people died. But that outbreak came to an end before the treatment could make its way into clinics, and until now there has been no opportunity to test it. The story of mAb114 goes back even further. Its pertinent antibody was isolated from a survivor of an epidemic of Ebola in the DRC in 1995.
Both treatments will now be deployed in the field—but, given the smallish size of the trial that approved them, doctors will be looking closely at their relative efficacies to determine whether, in light of more data, one is actually better than the other. Regardless of that, effective treatment will surely help break the epidemic directly, by stopping those cured passing on the virus. And it may help indirectly, too.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Two treatments for Ebola emerge from a clinical trial in AfricaOut of four experimental treatments, two have been found successful in the fight against Ebola
Read more »
New Drugs Cured 2 Ebola Patients: DoctorsEarlier this week, preliminary results from two trials in Congo suggested that the two drugs significantly reduced the risk of death from Ebola.
Read more »
New treatments show promise in fight against EbolaTwo of four experimental treatments being tested in the world's second-largest Ebola outbreak will now be offered to all patients after showing promise in saving lives, scientists and health officials announce.
Read more »
Breakthrough In Fight Against EbolaWhat the breakthrough in Ebola treatment demonstrates is how successful a public-private partnership can be in a relatively short period of time, with sufficient funding and coordination of government and pharmaceutical industry targeted efforts to save lives.
Read more »
Breakthrough In Fight Against EbolaWhat the breakthrough in Ebola treatment demonstrates is how successful a public-private partnership can be in a relatively short period of time, with sufficient funding and coordination of government and pharmaceutical industry targeted efforts to save lives.
Read more »
A cure for Ebola?A new, effective treatment for Ebola will help break the epidemic directly, stemming the spread of the deadly virus. The Economist’s healthcare correspondent Slavea Chankova tells kncukier about the breakthrough on our “Babbage” podcast
Read more »